Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02257541
Recruitment Status : Completed
First Posted : October 6, 2014
Results First Posted : March 30, 2020
Last Update Posted : March 30, 2020
Sponsor:
Collaborators:
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
University of Pittsburgh
Information provided by (Responsible Party):
Memorial Sloan Kettering Cancer Center

Tracking Information
First Submitted Date  ICMJE October 2, 2014
First Posted Date  ICMJE October 6, 2014
Results First Submitted Date  ICMJE February 13, 2020
Results First Posted Date  ICMJE March 30, 2020
Last Update Posted Date March 30, 2020
Actual Study Start Date  ICMJE October 2, 2014
Actual Primary Completion Date March 25, 2019   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: March 16, 2020)
  • Phase Ib Study: Number of Participants With Dose-Limiting Toxicities [ Time Frame: 1 year ]
    The phase Ib will be pursued in standard 3+3 format, based on toxicities encountered during the first cycle of therapy.
  • Phase Ib Portion: Response Rate (RR) [ Time Frame: 32 weeks ]
    (CR+PR, RECIST 1.1) and by CHOI criteria PHASE 1b PARTICIPANTS ONLY Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Original Primary Outcome Measures  ICMJE
 (submitted: October 2, 2014)
  • Phase Ib study: Maximum tolerated dose [ Time Frame: 1 year ]
    The phase Ib will be pursued in standard 3+3 format, based on toxicities encountered during the first cycle of therapy.
  • phase II portion: Response Rate (RR) [ Time Frame: 32 weeks ]
    (CR+PR, RECIST 1.1) and by CHOI criteria
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: March 16, 2020)
Phase Ib Study: Response Rate (RR) [ Time Frame: 32 weeks ]
defined by RECIST 1.1 criteria and by CHOI criteria,and by EORTC criteria PHASE 1b PARTICIPANTS ONLY Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR
Original Secondary Outcome Measures  ICMJE
 (submitted: October 2, 2014)
Phase Ib Study: Response Rate (RR) [ Time Frame: 32 weeks ]
defined by RECIST 1.1 criteria and by CHOI criteria,and by EORTC criteria
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Official Title  ICMJE A Phase Ib/II Study of BGJ398 in Combination With Imatinib Mesylate in Patients With Untreated Advanced Gastrointestinal Stromal Tumor (GIST)
Brief Summary The goal of a phase Ib clinical trial is to find the doses of drugs that are safe. Although BGJ398 has been given to patients safely on its own, it has never been given together with imatinib mesylate. In this study, we will test the safety of taking BGJ398 with imatinib mesylate. The investigators will learn this by closely checking for side effects that the patient may experience. Side effects can be seen in laboratory studies, on physical examination, or by asking the patient.Once a dose has been determined to be safe, a larger Phase II study will be done in patients with advanced GIST who have never received any prior treatments.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 1
Phase 2
Study Design  ICMJE Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Advanced Gastrointestinal Stromal Tumor (GIST)
Intervention  ICMJE
  • Drug: BGJ398
  • Drug: Imatinib Mesylate
Study Arms  ICMJE Experimental: BGJ398 With Imatinib Mesylate
BGJ398 With Imatinib Mesylate In the phase Ib portion of the study, patients will receive imatinib at 400 mg once daily and BGJ398 at the standard 3+3 escalation doses for 21 days on, 7 days off (treatment schedule A).Using treatment schedule A, if dose level 1 to -2 is identified as the MTD and concern exists regarding therapeutic activity of BGJ398 at this dose level, expansions with higher dose levels (1 to 3) may be considered at the MSKCC PI's discretion, with modification of the treatment schedule. In this setting BGJ398 will be administered daily for one week followed by 3 weeks off and imatinib will be taken daily throughout the 4 week cycle period (treatment schedule B). In the phase II portion of the study, patients will receive imatinib at 400 mg once daily (standard of care first line imatinib dose) and BGJ398 at the RP2D and treatment schedule identified in the phase Ib portion of the study. One cycle is 28 days.
Interventions:
  • Drug: BGJ398
  • Drug: Imatinib Mesylate
Publications * Kelly CM, Shoushtari AN, Qin LX, D'Angelo SP, Dickson MA, Gounder MM, Keohan ML, Mcfadyen C, Sjoberg A, Singer S, DeMatteo RP, Hwang S, Heinemann MH, Francis JH, Antonescu CR, Chi P, Tap WD. A phase Ib study of BGJ398, a pan-FGFR kinase inhibitor in combination with imatinib in patients with advanced gastrointestinal stromal tumor. Invest New Drugs. 2019 Apr;37(2):282-290. doi: 10.1007/s10637-018-0648-z. Epub 2018 Aug 13.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: March 26, 2019)
16
Original Estimated Enrollment  ICMJE
 (submitted: October 2, 2014)
62
Actual Study Completion Date  ICMJE March 25, 2019
Actual Primary Completion Date March 25, 2019   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients must have pathologically confirmed GIST.
  • In the Phase Ib portion, must have locally advanced or metastatic GIST and have progressed on imatinib.
  • In the Phase II portion, patients must be newly diagnosed or imatinib treatment naïve in the advanced/metastatic setting. Prior adjuvant imatinib therapy is allowed as long as disease recurrence was documented ≥90 days after last dose of imatinib and imatinib has not yet been restarted.
  • Patients must be at least 18 years of age.
  • Disease must be measurable by RECIST 1.1.
  • ECOG Performance Status 0 or 1. Adequate renal, hepatic, and hematologic function as the following: Serum Creatinine ≤ 1.5 mg/dL, Total Serum Bilirubin ≤ 1.5 x upper limit of normal (ULN) unless due to Gilbert's Disease, Serum AST (SGOT) and/or ALT (SGPT) ≤ 2.5 x ULN (or ≤ 5.0 x ULN if considered due to tumor), ANC ≥ 1500/mm3, Platelets ≥ 100,000/mm3, and hemoglobin ≥ 10g/dL.
  • Patients of childbearing potential must have a negative blood pregnancy test within 14 days of treatment. Patients must agree to use a reliable barrier method of birth control during and for 3 months following the last dose of study drug.
  • Patient must have adequate cardiac function (left ventricular ejection fraction (LVEF) ≥50% as determined by a multigated acquisition (MUGA) scan or echocardiogram; and QTc interval ≤480 ms by Fridericia's formula (QTcF).
  • Patient must be able to take oral medications.
  • Patients must sign an informed consent document.

Exclusion Criteria:

  • For phase I, prior intolerance to imatinib at a dose of 400 mg daily.
  • For phase II, any receipt of cytotoxic, biologic, or immune therapy aimed to treat GIST except for adjuvant imatinib systemic therapy that concluded at least 90 days prior to registration. For Phase I, patients are eligible regardless of prior therapy.
  • Chronic liver disease (e.g., cirrhosis)
  • Known positive serology for HIV, active Hepatitis B, and/or active Hepatitis C infection.
  • Patients have a history or current evidence of Central Serous Retinopathy (CSR) or retinal vein occlusion (RVO) or major predisposing factors to CSR or RVO (e.g. uncontrolled glaucoma or ocular hypertension) in the opinion of the study ophthalmologist.
  • History of retinal degenerative disease
  • Active corneal disorder or keratopathy (e.g. corneal abrasion, bullous keratopathy)
  • Severe and/or uncontrolled medical disease, including:

    • Uncontrolled diabetes mellitus (A1c >8)
    • Chronic Kidney Disease Stage III or higher (Creatinine Clearance <60mL/min/m2 by Modified Diet in Renal Disease (MDRD) calculation)
    • Active, uncontrolled infection Known active brain metastasis unless they have been treated and shown documented radiographic stability for 28 days.
  • Known other active malignancy (other than malignancies which the investigator determines are unlikely to interfere with treatment and safety analysis).
  • Patients have clinically significant cardiovascular disease, including any of the following

    • Any history of acute coronary syndrome including myocardial infarction, stable or unstable angina, CABG, coronary angioplasty or stenting or known obstructive coronary artery disease.
    • Symptomatic chronic heart failure (New York Heart Association Criteria, Class II-IV)
    • Evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities < 6 months prior to screening except atrial fibrillation (AF) and paroxysmal supraventricular tachycardia (PSVT)
  • Any history of thrombotic cerebrovascular accident or other arterial thrombosis
  • Uncontrolled arterial hypertension (systolic blood pressure >155 mmHg or diastolic >95 mmHg) despite appropriate medical therapy.
  • History and/or current evidence of uncontrolled endocrine alterations of calcium/phosphate homeostasis, e.g., parathyroid disorders, history of parathyroidectomy, tumor lysis, tumoral calcinosis, etc.
  • Impairment of gastrointestinal function or gastrointestinal disease (e.g., uncontrolled ulcerative disease; uncontrolled nausea, vomiting, diarrhea; chronic malabsorption syndrome).
  • Patients with major surgery within 3 weeks prior to study entry or who have not recovered from side effects of such procedure.
  • Women who are pregnant or lactating.
  • Sexually active males, unless they use a condom during intercourse while taking the drug and for 15 days after stopping treatment. They should not father a child in this period. A condom is required to be used also by vasectomized men in order to prevent delivery of the drug via seminal fluid.
  • Patients with any significant history of non-adherence to medical regimens or with inability to grant reliable informed consent.
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE United States
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02257541
Other Study ID Numbers  ICMJE 14-140
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Memorial Sloan Kettering Cancer Center
Study Sponsor  ICMJE Memorial Sloan Kettering Cancer Center
Collaborators  ICMJE
  • Dana-Farber Cancer Institute
  • M.D. Anderson Cancer Center
  • University of Pittsburgh
Investigators  ICMJE
Principal Investigator: William Tap, MD Memorial Sloan Kettering Cancer Center
PRS Account Memorial Sloan Kettering Cancer Center
Verification Date March 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP